Cadila Healthcare Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Cadila Healthcare Limited Pharmaceutical Export Portfolio Dataset — 41 Products, $34.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cadila Healthcare Limited — Pharmaceutical Exporter Profile (2026) | 41 Products, $34.9M Trade | TransData Nexus

Cadila Healthcare Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $34.9M Total Trade · DGFT Verified

Cadila Healthcare Limited is an Indian pharmaceutical exporter with a total trade value of $34.9M across 41 products in 17 therapeutic categories. Based on 814 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Carvedilol ($4.9M), Losartan ($3.6M), Spironolactone ($3.0M).

Cadila Healthcare Limited — Export Portfolio & Destination Treemap

Cadila Healthcare Limited pharmaceutical export portfolio — 41 products across 17 therapeutic categories. Source: Indian Customs (DGFT).

Who is Cadila Healthcare Limited? — Company Overview & Market Position

Cadila Healthcare Limited, now known as Zydus Lifesciences Limited, is a leading Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat. Established in 1952 by the late Mr. Ramanbhai B. Patel, the company has evolved into a fully integrated global healthcare provider. In 1995, the group restructured, forming Cadila Healthcare under the Zydus group, marking a significant milestone in its growth trajectory.

The company operates across the entire pharmaceutical value chain, encompassing research, development, production, marketing, and distribution of pharmaceutical products. Its diverse portfolio includes formulations, active pharmaceutical ingredients (APIs), animal healthcare products, and wellness products. Zydus Lifesciences Limited is publicly listed on the National Stock Exchange of India under the ticker symbol CADILAHC.

What Does Cadila Healthcare Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Carvedilol$4.9M 2Losartan

Product Portfolio — Top 30 by Export Value

Cadila Healthcare Limited exports 41 pharmaceutical products across 17 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Carvedilol	Cardiovascular	$4.9M	112	3.1%	8
2	Losartan	Cardiovascular	$3.6M	72	1.2%	13
3	Spironolactone	Diuretics	$3.0M	59	1.2%	6
4	Iron	Vitamins & Supplements	$2.9M	57	0.6%	13
5	Chloroquine	Antimalarial & Antiparasitic	$2.8M	55	1.2%	3
6	Hydroxychloroquine	Antimalarial & Antiparasitic	$2.7M	54	1.4%	3
7	Mesalamine	Gastrointestinal	$2.0M	41	0.1%	3
8	Meloxicam	Analgesics & Antipyretics	$1.5M	39	0.5%	9
9	Apixaban	Cardiovascular	$1.0M	23	0.6%	15
10	Nystatin	Antifungals	$950.0K	19	1.8%	8
11	Budesonide	Respiratory	$787.7K	22	0.4%	8
12	Anastrozole	Advanced Oncology	$650.0K	13	0.4%	7
13	Doxycycline	Antibiotics	$650.0K	13	0.5%	7
14	Methylprednisolone	Corticosteroids	$650.0K	13	2.2%	8
15	Oseltamivir	Antivirals	$650.0K	13	0.5%	11
16	Acyclovir	Antivirals	$500.0K	10	0.4%	12
17	Leflunomide	Immunosuppressants	$500.0K	10	3.4%	6
18	Letrozole	Advanced Oncology	$420.2K	11	1.3%	8
19	Atenolol	Cardiovascular	$400.0K	8	1.0%	13
20	Amiodarone	Cardiovascular	$328.5K	9	0.4%	11
21	Fluticasone	Respiratory	$318.5K	19	0.2%	11
22	Salmeterol	Respiratory	$307.6K	16	0.4%	12
23	Azathioprine	Immunosuppressants	$300.0K	6	0.9%	4
24	Trastuzumab	Advanced Oncology	$300.0K	6	0.4%	12
25	Formoterol	Respiratory	$299.9K	25	0.3%	9
26	Theophylline	Respiratory	$260.5K	11	1.7%	12
27	Allopurinol	Lipid & Metabolism	$250.0K	5	0.1%	14
28	Indomethacin	Analgesics & Antipyretics	$250.0K	5	2.7%	6
29	Sirolimus	Immunosuppressants	$250.0K	5	1.7%	3
30	Isosorbide	Cardiovascular	$238.5K	13	0.5%	14

Cadila Healthcare Limited exports 41 pharmaceutical products across 17 therapeutic categories with a total export value of $34.9M. The top category is Cardiovascular (31.3% of portfolio), followed by Antimalarial & Antiparasitic (16.1%), reflecting a diversified portfolio where the top 5 products account for only 48.9% of total value.

Showing top 30 of 41 products. Contact us for complete data.

Cadila Healthcare Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Zydus Lifesciences Limited boasts a robust manufacturing infrastructure with facilities across multiple locations in India, including Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim. These state-of-the-art plants adhere to stringent international standards, ensuring the production of high-quality pharmaceutical products. The company's manufacturing capabilities are further enhanced by its presence in the United States and Brazil, facilitating a global reach.

3Key Leadership

The company is led by Mr. Pankaj R. Patel, who serves as the Chairman and Managing Director. Under his leadership, Zydus Lifesciences Limited has achieved significant milestones, including the development of Lipaglyn, the world's first drug approved for the treatment of diabetic dyslipidemia.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Cadila Healthcare Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Zydus Lifesciences Limited has a strong presence in regulated markets such as the United States, Europe, the United Kingdom, Australia, and Japan. The company has received approvals from regulatory bodies like the US FDA, EMA, and TGA, facilitating market access in these regions. Its product portfolio includes a range of formulations that meet the stringent requirements of these markets.

2Emerging Markets

The company has expanded its footprint in emerging markets across Africa, Latin America, and Southeast Asia. Zydus Lifesciences Limited's commitment to quality is demonstrated by its WHO prequalification, enabling access to these markets. This strategic expansion aligns with the company's mission to provide affordable healthcare solutions globally.

3Geographic Strategy

Zydus Lifesciences Limited has strategically diversified its operations across various geographies, mitigating concentration risk. The company's global presence, including in regulated and emerging markets, reflects its strategic direction to achieve sustainable growth and address diverse healthcare needs worldwide.

Cadila Healthcare Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

The company's manufacturing facilities are registered with the US FDA, and it has a portfolio of approved Abbreviated New Drug Applications (ANDAs). Zydus Lifesciences Limited has filed Drug Master Files (DMFs) for various products, ensuring compliance with FDA standards. The company's facilities have undergone inspections, with the topical manufacturing facility at Changodar, Ahmedabad, receiving an Establishment Inspection Report (EIR) from the US FDA in August 2016, indicating successful closure of inspection points.

2WHO & EU GMP

Zydus Lifesciences Limited's manufacturing facilities comply with Good Manufacturing Practice (GMP) standards set by the World Health Organization (WHO) and the European Union (EU). The company's commitment to quality is evident in its adherence to these international standards, ensuring the production of safe and effective pharmaceutical products.

3CDSCO & Indian Regulatory

In India, Zydus Lifesciences Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained approvals from state drug controllers. The company has received No Objection Certificates (NOCs) for export, facilitating its international trade operations.

Cadila Healthcare Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Zydus Lifesciences Limited operates in a competitive landscape with key players such as Sun Pharmaceutical Industries, Cipla, and Dr. Reddy's Laboratories. The company's diverse product portfolio, including formulations across 17 therapeutic categories, positions it favorably in the market. Its focus on both regulated and emerging markets enhances its competitive edge.

2Key Differentiators

Zydus Lifesciences Limited's unique strengths include its comprehensive product portfolio, spanning 41 products across 17 therapeutic categories, and its strong presence in both regulated and emerging markets. The company's commitment to quality, demonstrated by its adherence to international GMP standards, and its focus on innovation, exemplified by the development of Lipaglyn, further distinguish it in the pharmaceutical industry.

3Strategic Position

Zydus Lifesciences Limited's current strategic direction encompasses the development of generics, specialty products, biosimilars, and contract development and manufacturing organization (CDMO) services. The company's future outlook includes expanding its global footprint, enhancing its product pipeline, and addressing unmet healthcare needs through innovation and strategic partnerships.

Buyer Due Diligence Brief — Evaluating Cadila Healthcare Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Zydus Lifesciences Limited has a strong track record in manufacturing and exporting pharmaceutical products, with a total export value of $34.9 million USD and 814 shipments across 41 products in 17 therapeutic categories. The company's top five products—Carvedilol, Losartan, Spironolactone, Iron, and Chloroquine—account for 48.9% of its export portfolio, indicating a diversified product range. The company's adherence to international quality standards and its presence in both regulated and emerging markets underscore its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm through the US FDA's official website or the company's regulatory filings.

WHO-GMP Certification: Check the World Health Organization's official website for prequalification status.

Frequently Asked Questions — Cadila Healthcare Limited

How many pharmaceutical products does Cadila Healthcare Limited export from India?

Cadila Healthcare Limited exports 41 pharmaceutical products across 17 therapeutic categories. The top exports are Carvedilol ($4.9M), Losartan ($3.6M), Spironolactone ($3.0M), Iron ($2.9M), Chloroquine ($2.8M). Total export value is $34.9M.

What is Cadila Healthcare Limited's total pharmaceutical export value?

Cadila Healthcare Limited's total pharmaceutical export value is $34.9M, based on 814 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Cadila Healthcare Limited cover?

Cadila Healthcare Limited exports across 17 therapeutic categories. The largest are Cardiovascular (31.3%, 9 products), Antimalarial & Antiparasitic (16.1%, 3 products), Diuretics (8.5%, 1 products).

Get Full Cadila Healthcare Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.